{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:11:55Z","timestamp":1779289915327,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12891-016-1275-5","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T23:18:57Z","timestamp":1476314337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis"],"prefix":"10.1186","volume":"17","author":[{"given":"Eva","family":"Balazcs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Bickham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Frontera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Stryszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Popmihajlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Peloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"1275_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379\u201390.","journal-title":"Lancet"},{"key":"1275_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","volume":"10","author":"H Breivik","year":"2006","unstructured":"Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287\u2013333.","journal-title":"Eur J Pain"},{"key":"1275_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2012.06.002","volume":"42","author":"S Brophy","year":"2013","unstructured":"Brophy S, Davies H, Dennis MS, Cooksey R, Husain MJ, Irvine E, et al. Fatigue in ankylosing spondylitis: treatment should focus on pain management. Semin Arthritis Rheum. 2013;42:361\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"1275_CR4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"1275_CR5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis Jr JC, Dijkmans B, et al. ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442\u201352.","journal-title":"Ann Rheum Dis"},{"key":"1275_CR6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2016;68: 282\u201398.","journal-title":"Arthritis Rheumatol"},{"key":"1275_CR7","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/rheumatology\/kes066","volume":"51","author":"R Berg van den","year":"2012","unstructured":"van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford). 2012;51:1388\u201396.","journal-title":"Rheumatology (Oxford)"},{"key":"1275_CR8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1275_CR9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756\u201365.","journal-title":"Arthritis Rheum"},{"key":"1275_CR10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 2016;75:1438\u201343.","journal-title":"Ann Rheum Dis"},{"key":"1275_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1358\/dot.2004.40.5.850488","volume":"40","author":"AK Matsumoto","year":"2004","unstructured":"Matsumoto AK, Cavanaugh Jr PF. Etoricoxib. Drugs Today (Barc). 2004;40:395\u2013414.","journal-title":"Drugs Today (Barc)"},{"key":"1275_CR12","doi-asserted-by":"crossref","unstructured":"Wang R, Dasgupta A, Ward MM: Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 2015, annrheumdis-207677.","DOI":"10.1136\/annrheumdis-2015-207677"},{"key":"1275_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2474-12-165","volume":"12","author":"PM Peloso","year":"2011","unstructured":"Peloso PM, Gammaitoni A, Smugar SS, Wang H, Moore AR. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord. 2011;12:165. doi: 10.1186\/1471-2474-12-165 .","journal-title":"BMC Musculoskelet Disord"},{"key":"1275_CR14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2165\/00003495-200969110-00008","volume":"69","author":"KF Croom","year":"2009","unstructured":"Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009;69:1513\u201332.","journal-title":"Drugs"},{"key":"1275_CR15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/ard.2004.029611","volume":"64","author":"L Gossec","year":"2005","unstructured":"Gossec L, van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis. 2005;64:1563\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1275_CR16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52:1205\u201315.","journal-title":"Arthritis Rheum"},{"key":"1275_CR17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"1275_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/rheumatology\/kep005","volume":"48","author":"B Combe","year":"2009","unstructured":"Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009;48:425\u201332.","journal-title":"Rheumatology (Oxford)"},{"key":"1275_CR19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771\u201381.","journal-title":"Lancet"},{"key":"1275_CR20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302\u20138.","journal-title":"BMJ"},{"key":"1275_CR21","doi-asserted-by":"crossref","unstructured":"Exarchou S, Lie E, Lindstrom U, Askling J, Forsblad-d\u2019Elia H, Turesson C et al.: Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 2015, annrheumdis-207688.","DOI":"10.1136\/annrheumdis-2015-207688"},{"key":"1275_CR22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","volume":"369","author":"L Laine","year":"2007","unstructured":"Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007;369:465\u201373.","journal-title":"Lancet"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-016-1275-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T10:38:55Z","timestamp":1568457535000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-016-1275-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1186\/s12891-016-1275-5","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]},"article-number":"426"}}